Dr SOMME François

Fiche personne

Coordonnées

Institut Strauss
3 rue de la Porte de l'Hôpital
BP 30042
67065 STRASBOURG Cedex

Territoire

Alsace

Statut

Hospitalier

Affiliation

Institut Strauss (IS)

Équipes/plateformes

Médecine nucléaire et imagerie moléculaire

Recherche

Expertises :
- Médecine nucléaire

Publications

Prognostic value of [F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan.

Frega J, Somme L, Martin T, Petit T, Salvadori J, Bund C, Somme F

Eur J Nucl Med Mol Imaging. 2026 07 1;:

Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation.

Lienhardt O, Allegrini O, Poterszman N, Ritzenthaler F, Porot C, Mazzara C, Somme F, Salvadori J

EJNMMI Phys. 2026 04 16;:

[177Lu]Lu-PSMA extravasation: from quantitative imaging to clinical guidelines.

Salvadori J, Allegrini O, Ritzenthaler F, Poterszman N, Porot C, Malezieux X, Potel M, Somme F

Phys Med Biol. 2026 04 15;:

Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer.

Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barthélémy P, Somme F

Theranostics. 2025 03 3;15(9):3724-3732

A Hangover Under 177 Lu-PSMA-617 Therapy : A Red Flag for Brain 68 Ga-PSMA-11 PET/MRI?

Poterszman N, Somme L, Bund C, Hutt E, Somme F

Clin Nucl Med. 2024 06 1;49(6):582-583

A bicentric retrospective study of the correlation of EAU BCR risk groups with F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence.

Poterszman N, Merlin C, Margail C, Ouvrard E, Imperiale A, Somme F

Sci Rep. 2024 05 13;14(1):10908

Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?

Ouvrard E, Kaseb A, Poterszman N, Porot C, Somme F, Imperiale A

Front Med (Lausanne). 2024 01 15;10:1320574

Impact of pelvic dynamic acquisition on final reading of F-Fluorocholine positron emission tomography in patients with prostate adenocarcinoma: True need or unnecessary burden?

Latge A, Heimburger C, Severac F, Meyer N, Somme F, Imperiale A

J Med Imaging Radiat Oncol. 2021 Jul 29;:

18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST.

Somme F, Bender L, Kurtz JE, Gantzer J, Imperiale A

Clin Nucl Med. 2021 Mar 16;:

High risk of recurrence for grade II meningioma: a 10-year multicenter analysis of prognosis factors.

Bender L, Somme F, Lhermitte B, Ahle G, Boone M, Blonski M, Pouget C, Truc G, Cebula H, Noël G

Chin Clin Oncol. 2021 Mar 10;:

Usefulness of F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature.

Somme F, Bender L, Namer IJ, Noël G, Bund C

Cancer Imaging. 2020 Oct 6;20(1):70

Solid pseudopapillary tumor should be part of differential diagnosis of focal pancreatic lesions with increased F-FDOPA uptake.

Somme F, Montaz-Rosset MS, Averous G, Deur J, Goichot B, Bachellier P, Addeo P, Imperiale A

Clin. Endocrinol. (Oxf). 2020 Apr 20;:

Complete Response of a Pleural, Hepatic, and Splenic Metastatic Primary Breast Angiosarcoma Using Gemcitabine Monotherapy.

Bender L, Gantzer J, Somme F, Weingertner N, Kurtz JE

JCO Oncol Pract. 2020 Feb 18;:JOP1900609

Metabolomic profile of aggressive meningiomas by using high-resolution magic angle spinning nuclear magnetic resonance.

Bender L, Somme F, Ruhland E, Cicek E, Bund C, Namer IJ

J. Proteome Res.. 2019 Nov 4;:

Evaluation of Oxalate Osteopathy Secondary to Hyperoxaluria With 18F-FDG PET/CT and 99mTc-HMDP Bone Scan.

Somme F, Blondet C, Matuszak J, Heimburger C

Clin Nucl Med. 2019 02;44(2):123-124

Fiche personne Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques